Tag - parkinson’s disease

Markets

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...

May 6, 2020

Feature

Titan’s next ProNeura implant could be game changer in PD

By Len Zehr After gaining widespread attention with its FDA-approved Probuphine implant for the maintenance treatment of opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is setting out to develop an implant to...

October 10, 2017

Feature

Titan’s next ProNeura-based implant dovetails with PD awareness month

By Len Zehr After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to...

April 25, 2017

Feature

Titan Pharma advancing pipeline in PD, other disorders

By Len Zehr Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...

October 13, 2015

Feature

International Stem Cell scores neuronal goal in treating Parkinson’s

By Len Zehr Positive animal data reported by International Stem Cell (OTCBB:ISCO) last month brings the company one step closer to starting human testing of its stem cell technology to treat Parkinson’s disease. “We...

April 2, 2013

Tag - parkinson’s disease

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Titan’s next ProNeura implant could be game changer in PD

Titan’s next ProNeura-based implant dovetails with PD awareness month

Titan Pharma advancing pipeline in PD, other disorders

International Stem Cell scores neuronal goal in treating Parkinson’s

General

More